Monoclonal antibody therapy for COVID-positive patients in northern NSW

The Therapeutic Goods Administration (TGA) has provisionally approved several monoclonal antibodies for COVID-19 treatment.

What are monoclonal antibodies?  

Monoclonal antibodies are laboratory-made proteins that mimic or enhance the human immune system response to fight against harmful antigens such as viruses.

Monoclonal antibodies that can specifically target surface viral proteins to block the viral entry to host cells can be used for preventing and treating COVID-19.  

In Australia, the TGA has provisionally approved sotrovimab, tixagevimab and cilgavimab (Evusheld) and casirivimab+imdevimab (Ronapreve).

Sotrovimab (Xevudy®)

Sotrovimab works by binding to the spike protein of the virus that causes COVID-19. This binding blocks the virus entering human cells and multiplying in the body. A recent study indicates that sotrovimab probably reduces the risk of being admitted to hospital or dying if used within 5 days of onset of COVID-19 symptoms.

The National COVID-19 Clinical Evidence Taskforce states sotrovimab is medically indicated for:

  • adults and pregnant people in the second or third trimester if: 
    • within 5 days of onset of symptoms
    • not fully vaccinated or fully vaccinated but significantly immunosuppressed
    • not requiring oxygen
    • one or more medical risk factors for disease progression: 
      • diabetes requiring medication 
      • BMI is more than 30 
      • chronic kidney disease (eGFR is less than 60) 
      • congestive heart failure NYHA class 2 or higher 
      • COPD 
      • moderate to severe asthma requiring regular inhaled steroid or a course of oral steroids in the last 12 months 
      • age > 55 years or > 35 years if Aboriginal or Torres Strait Islander or Pasifika
    • children who: 
      • are aged more than 12 years
      • weigh more than 99th centile for their gender and age or have type 2 diabetes mellitus
      • are significantly immunosuppressed due to cancer treatment, organ transplant, medication or immune deficiency
      • are within 5 days of symptom onset
      • have a serious chronic condition which requires: 
        • specialist assessment more than 4 times a year 
        • 4 or more regular medications
        • CPAP, BiPAP or oxygen for a respiratory condition
        • feeding assistance with either nasogastric or PEG tube.

For a definition of ‘immunocompromised’, see ATAGI recommendations on the use of a third primary dose of COVID-19 vaccine in severely immunocompromised patients. 

Contraindication and precautions

  • Hypersensitivity: contraindicated in patients with known hypersensitivity to sotrovimab, or any of ingredients.  Exercise caution in patients with a history of anaphylaxis to other medicines.
  • First trimester pregnancy and breastfeeding.
  • There is potential for placental transfer  to the developing foetus.
  • No information is available on the use of sotrovimab during breastfeeding. The amount present in breastmilk is likely to be very low, as sotrovimab is a large protein molecule but the median elimination half-life is 49 days, therefore the discontinuation of breastfeeding may be considered if appropriate. 
  • The effect of sotrovimab on fertility is unknown. 
  • Paediatric population: The safety and efficacy of sotrovimab has not been established in children under 12 years of age or weighing less than 40 kg. 

Drug  interactions  

  • There have been no formal drug interaction studies conducted with sotrovimab.
  • The current recommendation is that COVID-19 vaccinations should be delayed until 90 days after administration of monoclonal antibodies to avoid potential interference with the immune response.


The current treatment is a single dose (500 mg) of sotrovimab given by intravenous infusion in a hospital setting. The patient must be observed during the infusion and for at least 60 minutes post infusion to ensure no adverse reactions. Infusion reactions include fever, chills, dizziness, dyspnoea, pruritus and rash. If these are mild to moderate, the infusion may be slowed or stopped and the reaction treated accordingly before being restarted. Anaphylactic reactions are rare but are a medical emergency. 

Side effects  

Reported common effects of sotrovimab  include diarrhoea (1%) and hypersensitivity reactions (includes rash (2%), infusion-related reaction, bronchospasm). Following the observation period, patients should be provided with advice regarding post infusion requirements, including adverse effects and who to contact for more information. All adverse events should be reported via the TGA. 

Referring patients for monoclonal antibody therapy

Dr Chris Bentley
Northern NSW Local Health District Virtual COVID-19 Care Service (VCCS) 

A monoclonal antibody is being used for COVID treatment in specific populations that are at risk of severe complications of a COVID-19 infection. 

It is an intravenous infusion that is administered over a one-hour period in Lismore Base Hospital. 

It works by binding to the spike protein and blocking the virus from entering human cells. It can reduce the risk of getting very sick and hospitalisations. 

It is critical this is an early referral, as it only works in the first 5 days of symptoms. 

Use the northern NSW referral form on HealthPathways and ring the VCCS on 1800 848 919. 

Please do this the earliest in the day as possible and in business hours, preferably before 3 pm to prevent an unnecessary overnight hospital admission, as hospital beds are very valuable in this current climate. 

Need HealthPathways login details?

Username: manchealth
Password: conn3ct3d

For more information 

View the Agency for Clinical Innovation’s fact sheet – Model of Care for the Use of anti‑SARS‑COV‑2 Monoclonal Antibodies for Adults with Mild and Moderate COVID‑19 (PDF, 325 KB).

View the Australian National COVID-19 Clinical Evidence Taskforce’s flowchart – Disease-modifying treatments for adults with COVID-19 (PDF, 255 KB).

Update provided 21 April 2022.

As you know, Lismore Skin Clinic in Molesworth Street was destroyed in the recent floods, and we are trying to rebuild the site as soon as we can.

In the meantime we will be moving to St Vincent’s Hospital Specialist Medical Centre – Level 4, Suite 12 – 20 Dalley Street Lismore.

We hope to be up and running in the next two weeks (by early to mid May 2022) and our receptionists will soon begin calling our patients to rebook their appointments and catch up with their needs.

Once we have a firm opening date we will update this notification.

Our email address – [email protected] and our phone number – 02 6621 3500 will remain the same as in the past. Only the address changes for a while.

We look forward to seeing you soon in our new premises.

Many thanks for your patience and understanding in these heartbreaking times – stay safe.

Dr Gudmundsen and the Team from Lismore Skin Clinic


Contact our Education Team

  • This field is for validation purposes and should be left unchanged.

Nigel Cronin
Senior Manager, Education
[email protected]
0437 169 786
02 6627 3390
Based on Bundjalung Country in Lismore

Bronwyn Thirkell
Centre for Healthcare Knowledge & Innovation and Education and Events Coordinator NNSW
[email protected]
0437 027 751
02 6618 5445
Based on Bundjalung Country in Ballina

Krissi Devlin
Education and Events Coordinator MNC
[email protected]
0447 407 473
02 6659 1808
Working days: Monday Thursday.
Based on Gumbaynggirr Country in Coffs Harbour

Mental Health Practitioner Directory

Frequently Asked Questions

Any AHPRA or AASW registered mental health practitioner providing services in the Mid North Coast and/or Northern NSW.

Social workers, psychotherapists and counsellors are ineligible to list in the directory.

By listing, you will let GPs, other referrers and consumers know that you are practising in Mid North Coast and/or Northern NSW. You can provide information such as where you are located, the services you provide, the population groups you support and your clinical interests.

No, the directory is a free service provided by Healthy North Coast.

This directory enables you to provide real-time information about your availability to accept referrals, as well as how long people may have to wait for an appointment. You can update this information as your availability changes. This will help GPs and other referrers ensure they only refer clients to practitioners who have the capacity to see them.

It also has a range of advanced search options and supports printing and bookmarking of search results.

You can choose to display your email address and your phone number so that people can contact you directly. You may prefer not to display these, in which case people can contact you by completing an enquiry form located in the Directory. Your choices can be updated anytime.

You can indicate wait times for an appointment for a new client or that you are currently unable to accept new referrals. You can also choose whether to display or hide your contact details. You can update your choices at any time.

Yes, you can update your listing or remove it at any time by clicking the “update practitioner details” button on your listing. You will receive a secure website link to your nominated admin email that will enable you to make changes, delete or put your listing on hold. You can also show when you are taking extended leave or are not available for a specific period, rather than completely removing your listing.

We will also send you an email every three months (90 days) prompting you to check that your information is up to date.

You will be responsible for managing the information in your listing and ensuring that it is up to date. You will also be asked to check the information before it is published in the directory.

We will also send you an email every three months (90 days) prompting you to check that your information is up to date so that the directory displays accurate information.

You can read the full Terms of Use by clicking here.